is atezolizumab approved in china?
434914
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer ...
1331860
Summary. Idarucizumab is the first agent to be licensed in the UK that reverses the anticoagulant effect of a non‑vitamin K antagonist oral anticoagulant (NOAC). ... Regulatory status: Idarucizumab (Praxbind, Boehringer Ingelheim Limited) was launched in the UK in December 2015.
776994
['reslizumab (Cinqair)', 'mepolizumab (Nucala)', 'omalizumab (Xolair)', 'benralizumab (Fasenra)']
1448199
Eculizumab is used for the treatment of the blood disorders: paroxysmal nocturnal hemoglobinuria (PNH) atypical Hemolytic Uremic Syndrome (aHUS)
650105
['Atezolizumab.', 'Avastin (Bevacizumab)', 'Bevacizumab.', 'Cabometyx (Cabozantinib-S-Malate)', 'Cabozantinib-S-Malate.', 'Cyramza (Ramucirumab)', 'Keytruda (Pembrolizumab)', 'Lenvatinib Mesylate.']
194042
Yes and no. Some medical colleges in China are recognized by the PMDC on Pakistan others are not.. Chinese medical school graduates have to pass a series of exams set up by the PMDC to test the knowledge and clinical skills of the graduate … only then they are recognized as medical doctors..
178995
['Prednisone.', 'Tacrolimus (Prograf)', 'Cyclosporine (Neoral)', 'Mycophenolate Mofetil (CellCept)', 'Imuran (Azathioprine)', 'Rapamune (Rapamycin, Sirolimus)']
345315
Taltz (ixekizumab) and Cosentyx (secukinumab) are biologics, as are the older tumor necrosis factor (TNF) inhibitors. "There's a big gap there in terms of patients seeking out or having access to more efficacious medicines. Having Taltz come to the market gives physicians more options," Morison added.
636541
Project Orbis: FDA approves acalabrutinib for CLL and SLL. On November 21, 2019, the Food and Drug Administration approved acalabrutinib (CALQUENCE, AstraZeneca) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
404153
Ryzodeg ® received its first regulatory approval in December 2012 and European Medicines Agency approval in January 2013. Since then, Ryzodeg ® has been approved in more than 90 countries, including the US in September 2015. It is now commercially available in 20 countries.
1153326
It can take up to 6 months after the last dose for vedolizumab to be completely eliminated from the body, so some effects might appear during this time. Some side effects are mild and will go away on their own, or following a slight change to the infusion programme.
655597
Health Canada has just approved a drug called Benlysta (belimumab) specifically for the treatment of systemic lupus erythematosus (SLE), the full name of lupus. It's expected to become available to patients in Canada in September.
113022
The CDC and WHO recommend the following vaccinations for China: hepatitis A, hepatitis B, typhoid, yellow fever, Japanese encephalitis, rabies, meningitis, polio, measles, mumps and rubella (MMR), Tdap (tetanus, diphtheria and pertussis), chickenpox, shingles, pneumonia and influenza.
1203191
Infliximab is not FDA approved for uveitis or ocular inflammation. It is currently FDA approved for Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis and plaque psoriasis, and ankylosing spondylitis.
464582
Omalizumab is not approved for use in pregnant women but it was assigned to pregnancy category B by the FDA after Namazy et al published "The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy" (J Allergy Clin Immunol 2015;135:407-12).
232934
Opdivo and Keytruda approved in new lung cancer uses. The FDA has approved Merck's Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC), after green-lighting Bristol-Myers Squibb's (BMS) rival blockbuster Opdivo (nivolumab) for small cell lung cancer (SCLC).
1119486
The European Commission has granted marketing authorization for Yescarta (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.